Oral anticoagulants: Optimizing venous thromboembolism management

Oral anticoagulants: Optimizing venous thromboembolism management

A decade ago, oral anticoagulants were limited to Vitamin K antagonists, i.e., warfarin. Since 2010, the US Food and Drug Administration has approved several non-Vitamin K oral anticoagulants: dabigatran is a direct thrombin inhibitor, while apixaban, edoxaban, and rivaroxaban are direct factor Xa i...

Full description

Bibliographic Details
Main Author: Fahad A S. Aleidan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Journal of Applied Hematology
Subjects:
anticoagulants
bleeding
management
reversal agent
venous thromboembolism
Online Access:http://www.jahjournal.org/article.asp?issn=1658-5127;year=2019;volume=10;issue=4;spage=111;epage=119;aulast=S.

Internet

http://www.jahjournal.org/article.asp?issn=1658-5127;year=2019;volume=10;issue=4;spage=111;epage=119;aulast=S.

Similar Items